[go: up one dir, main page]

WO2025165681A1 - Compositions de sérum avec additif pour administration oculaire chez des animaux - Google Patents

Compositions de sérum avec additif pour administration oculaire chez des animaux

Info

Publication number
WO2025165681A1
WO2025165681A1 PCT/US2025/013143 US2025013143W WO2025165681A1 WO 2025165681 A1 WO2025165681 A1 WO 2025165681A1 US 2025013143 W US2025013143 W US 2025013143W WO 2025165681 A1 WO2025165681 A1 WO 2025165681A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
blood
derived serum
serum
examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/013143
Other languages
English (en)
Inventor
Brent J. BOWMAN
Nathan D. HEIN
Troy R. OPENSHAW
Daniel J. CRANE
Aaron P. BAKKEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serorepair LLC
Original Assignee
Serorepair LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serorepair LLC filed Critical Serorepair LLC
Publication of WO2025165681A1 publication Critical patent/WO2025165681A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Definitions

  • the present disclosure relates generally to compositions for ocular delivery in animals, including methods of manufacture and apparatuses for preparing the same.
  • serum-based lubricants are known to effectively mitigate corneal degradation and ulcer development, while also tending to stabilize the cornea scaffolding. Additionally, serum-based lubricant products can be beneficial for certain other conditions, such as indolent ulcers, corneal trauma, allergic conjunctivitis, KCS (dry eye), and post-operative care.
  • serum-based lubricants are limited in their application of a wider variety of ocular conditions.
  • serum-based lubricants and especially autologous serums
  • Transmission of species-specific diseases and conditions is also a risk with allogeneic serums from presumed healthy donors.
  • many veterinarians use over-the-counter eye drop solutions that are reasonably effective, but substantially less effective than their serum counterpart solutions. Accordingly, there is a constant need for serum-based solutions that can be combined with other therapeutic elements and made readily available for consumers in a cost-effective manner.
  • An aspect of the present disclosure relates to a composition for topical ophthalmic delivery in companion animals.
  • the composition can include a blood-derived serum and an antibiotic.
  • the antibiotic comprises an active ingredient from the fluoroquinolone family.
  • the antibiotic comprises an active ingredient that includes ciprofloxacin or levofloxacin.
  • the composition includes a ratio of the blood-derived serum relative to the antibiotic that is between about 2 to 1 (2: 1) to about 10 to 1 (10: 1).
  • the blood-derived serum comprises bovine serum.
  • compositions for topical ophthalmic delivery in companion animals in which the composition includes a blood-derived serum and an eye lubricant.
  • the eye lubricant can include sodium hyaluronate.
  • the eye lubricant can include hyaluronic acid.
  • the composition includes a ratio of the blood-derived serum relative to the eye lubricant that is between about 2 to 1 (2: 1) to about 10 to 1 (10: 1).
  • the blood- derived serum can include bovine serum.
  • compositions for topical ophthalmic delivery in companion animals in which the composition includes a blood-derived serum and an antihistamine.
  • the antihistamine can include pheniramine maleate.
  • the composition includes a ratio of the blood-derived serum relative to the eye lubricant that is between about 2 to 1 (2: 1) to about 10 to 1 (10:1).
  • the blood-derived serum can include bovine serum.
  • compositions for topical ophthalmic delivery in companion animals in which the composition includes a blood-derived serum and a vitamin.
  • the vitamin includes vitamin Bl.
  • the composition includes a ratio of the blood-derived serum relative to the vitamin that is between about 2 to 1 (2: 1) to about 10 to 1 (10: 1).
  • the blood-derived serum can include bovine serum.
  • compositions for topical ophthalmic delivery in companion animals in which the composition includes a blood-derived serum and a lysed white blood cell product.
  • the lysed white blood cell product includes a protein derived from the lysed white blood cell.
  • the blood- derived serum can include bovine serum.
  • compositions for topical ophthalmic delivery in companion animals in which the composition includes a blood-derived serum and an additive.
  • the additive can include at least one of an antibiotic, an antihistamine, a vitamin, or a lysed white blood cell product.
  • Additional aspects of the present disclosure include a method of manufacturing any and all compositions described, referred to, exemplified, or shown.
  • the method of manufacture includes one or more steps for mixing, product separation, storage, or packaging.
  • compositions described referred to, exemplified, or shown.
  • the apparatus is configured to perform one or more steps of mixing, product separation, storage, or packaging.
  • FIG. 2 illustrates an example fill station for preparing and packaging at least a portion of one or more compositions of the present disclosure
  • FIG. 4 illustrates an example eye dropper bottle being filled with an example composition (or a portion thereof) according to one or more examples of the present disclosure
  • FIG. 5 illustrates an example package including multiple eye dropper bottles filled with an example composition (or a portion thereof) according to one or more examples of the present disclosure.
  • the following disclosure relates to an eye drop solution for veterinarian use in companion animals, such as dogs, cats, and horses.
  • companion animals should be interpreted as non-food chain animals that are not typically used for human consumption.
  • the eye drop solution can include a blood-derived serum and an additive.
  • a blood-derived serum can refer to the fluid and solvent component of blood that does not play a role in clotting.
  • various additives can be implemented with the blood-derived serum. At least one of the additive or the blood-derived serum can constitute an active ingredient of a composition set forth in the present disclosure.
  • An active ingredient can refer to an agent or a mixture of agents that causes a desired therapeutic effect.
  • the package 500 can include various materials, sizes, shapes, and configurations of packaging. As shown, the package 500 can include a cardboard box configuration with rows and columns of the eye dropper bottles 502. In particular examples, the package 500 can include separate storage spaces for individually housing (and protecting) the eye dropper bottles 502. The package 500 can be conveniently shipped and/or stored (e.g., frozen or refrigerated) as an individual box or in bulk.
  • FIGS. 1-5 can be modified for different methods and implementations.
  • the processes, in particular, are merely illustrative, and alternative embodiments may omit, add to, reorder, and/or modify any aspect of the process flow shown, described, related to, or inferred by FIGS. 1-5.
  • various aspects described above can be machine operated or robotically operated.
  • various aspects described above can be implemented as part of an assembly line, conveyor system, or other automated/semi-automated system.
  • various aspects described above can be performed in one or more batches, or else performed according to various manufacturing methods (e.g., FIFO or first in, first out manufacturing).
  • an additive of the present disclosure includes an antibiotic.
  • the antibiotic can include an antimicrobial substance active in fighting (e.g., killing or inhibiting growth of) bacteria.
  • a blood-derived serum combined with an antibiotic can treat infections while also providing eye lubrication.
  • Some example bacterial infections that can be treated by the disclosed blood-derived serum combined with an antibiotic include blepharitis, corneal ulcers, pink eye, keratitis, conjunctivitis, other A. aerogenes, Rickettsiae, E. coli, and streptococci.
  • Various dosages or potencies can be implemented and at various different time intervals.
  • These or other potencies of the antibiotic can be added in many different ratios relative to a blood-derived serum to form a combined antibiotic-blood derived serum composition.
  • Some example ratios of the antibiotic relative to a blood-derived serum can include about 1 part antibiotic to about 1 part blood-derived serum (hereafter expressed in the form “X: Y”), about 1 :2 to about 1 : 10, about 1 :3 to about 1 :8, about 1 :4 to about 1 :6, about 2:1 to about 10: 1, about 3: 1 to about 8:1, or about 4: 1 to about 6: 1.
  • the antibiotic can be released (e.g, into the bloodstream of the animal and/or local ocular tissue of the animal) within a predetermined time interval, such as within about five seconds to about five hours, about thirty seconds to about five hours, about fifteen minutes to about five hours, about twenty-five minutes to about four hours, about thirty minutes to about three hours, about sixty minutes to about two hours, or about one hour.
  • an additive includes an antihistamine.
  • An antihistamine can include a drug class that targets histamine receptors (e.g., as a receptor antagonist or inverse agonist) of an animal.
  • Some examples of an antihistamine can include diphenhydramine, loratadine, chlorphenamine, cinnarizine, hydroxyzine, promethazine, acrivastine, cetirizine, fexofenadine, pyrilamine maleate, pheniramine maleate, tripelennamine, etc.
  • a blood-derived serum combined with an antihistamine can treat allergic reactions, cold symptoms, motion sickness, and/or vomiting.
  • Various dosages or potencies can be implemented and at various different time intervals.
  • Example potencies of the antihistamine can include about 0.1% to about 1% antihistamine, about 0.2% to about 0.5% antihistamine, or about 0.3% antihistamine.
  • These or other potencies of the antihistamine can be added in many different ratios relative to a blood-derived serum to form a combined antihistamine-blood derived serum composition.
  • Some example ratios of the antihistamine relative to a blood-derived serum can include about 1 part antihistamine to about 1 part blood-derived serum (hereafter expressed in the form “X:Y”), about 1 :2 to about 1 : 10, about 1 :3 to about 1 :8, about 1 :4 to about 1 :6, about 2: 1 to about 10: 1, about 3: 1 to about 8: 1, or about 4: 1 to about 6: 1.
  • the antihistamine can be released (e.g., into the bloodstream or local ocular tissue of the animal) within a predetermined time interval, such as within about five seconds to about five hours, about thirty seconds to about five hours, about fifteen minutes to about five hours, about twenty -five minutes to about four hours, about thirty minutes to about three hours, about sixty minutes to about two hours, or about one hour.
  • an additive can include an eye lubricant.
  • An eye lubricant can include a substance that cushions, moistens, hydrates, or soothes eyes.
  • An eye lubricant can also be osmoprotectant and/or bioprotectant (e.g., to help stabilize ocular cells and/or maintain or restore the tear film).
  • Some examples of an eye lubricant can include hyaluronic acid, sodium hyaluronate, viscoadaptive hyaluronan, viscoadaptive biopolymers, etc.
  • a blood-derived serum combined with an eye lubricant can treat acute or seasonal dry eyes.
  • Various dosages or potencies can be implemented and at various different time intervals.
  • Example potencies of an eye lubricant e.g., hyaluronic acid
  • These or other potencies of the eye lubricant can be added in many different ratios relative to a blood-derived serum to form a combined eye lubricant-blood derived serum composition.
  • Some example ratios of the eye lubricant relative to a blood-derived serum can include about 1 part eye lubricant to about 1 part blood-derived serum (hereafter expressed in the form “X:Y”), about 1 :2 to about 1 : 10, about 1 :3 to about 1 :8, about 1 :4 to about 1:6, about 2: 1 to about 10: 1, about 3 : 1 to about 8: 1, or about 4: 1 to about 6: 1.
  • the eye lubricant can be released or activated in the eye within a predetermined time interval, such as within about one second to about five hours, about thirty seconds to about five hours, about fifteen minutes to about five hours, about twenty-five minutes to about four hours, about thirty minutes to about three hours, about sixty minutes to about two hours, or about one hour.
  • an additive can include a vitamin, mineral, protein, amino acid, fats and fatty acids, and/or a supplement.
  • a vitamin can include a variety of essential nutrients and organic substances that an animal can use or produce to live. Vitamins can be either fat soluble or water soluble.
  • vitamins can include vitamin A, B vitamins (including Thiamin or vitamin Bl), vitamin C, vitamin D, vitamin E, vitamin K, choline, etc.
  • a mineral can include magnesium, potassium, sulphur, sodium phosphorous, calcium, chloride, iron, zinc, copper, selenium, iodine, chromium, fluorine, cobalt, molybdenum, boron, and manganese.
  • a protein can include casein, whey, and collagen.
  • Examples of an amino acid can include arginine, histidine, isoleucine, leucine, lysine, methionine, cysteine, phenylalanine, threonine, tryptophan, valine, taurine, etc.
  • fats and fatty acids can include linoleic acid, arachidonic acid, alpha-linoleic acid, eicosapentaenoic acid, and docosahexaenoic acid.
  • a supplement can include antioxidants, fish oil, organ meat, glucosamine, probiotics, etc.
  • a blood-derived serum combined with a vitamin can treat and/or prevent a host of different diseases and conditions.
  • a vitamin or other element mentioned above
  • Various dosages or potencies can be implemented and at various different time intervals.
  • Example potencies of a vitamin can vary by vitamin, animal species, breed, and/or weight (e.g., for thiamine administered to canines, about 0.5mg to about Img per pound about every twenty- four fours).
  • These or other potencies of the vitamin can be added in many different ratios relative to a blood-derived serum to form a combined vitamin-blood derived serum composition.
  • Some example ratios of the vitamin relative to a blood-derived serum can include about 1 part vitamin to about 1 part blood-derived serum (hereafter expressed in the form “X:Y”), about 1 :2 to about 1 : 10, about 1 :3 to about 1 :8, about 1 :4 to about 1 :6, about 2:1 to about 10: 1, about 3: 1 to about 8:1, or about 4: 1 to about 6: 1.
  • the vitamin can be released (e.g., into the bloodstream or local ocular tissue of the animal) within a predetermined time interval, such as within about one second to about five hours, about thirty seconds to about five hours, about fifteen minutes to about five hours, about twenty -five minutes to about four hours, about thirty minutes to about three hours, about sixty minutes to about two hours, or about one hour.
  • an additive includes a lysed white blood cell product.
  • lysed cell refers to a burst or ruptured cell.
  • a lysed cell can leave behind one or more products of interest.
  • a lysed white blood cell product can include one or more elements extracted from the lysing process.
  • a lysed white blood cell product can include proteins.
  • protein products from lysed white blood cells can include antibody proteins.
  • protein products from lysed white blood cells can include Myeloperoxidase, bactericidal/permeability-increasing protein (BPI), defensins, and the serine proteases neutrophil elastase, Proteinase 3 and cathepsin G, Alkaline phosphatase, lysozyme, NADPH oxidase, collagenase, lactoferrin, histaminase, cathelicidin, Cathepsin, gelatinase, collagenase, IL-IRA, Alpha 2-M, and sTNF.
  • BPI bactericidal/permeability-increasing protein
  • defensins defensins
  • the serine proteases neutrophil elastase Proteinase 3 and cathepsin G
  • Alkaline phosphatase Alkaline phosphatase
  • lysozyme NADPH oxidase
  • White blood cells can be lysed in a variety of ways (e.g., upon separating the white blood cells from other blood components).
  • the lysis method can include mechanical approaches (e.g., utilizing a wareing blender polytron with rotating blades that can grind and disperse cells).
  • the lysis method can include liquid homogenization (e.g., utilizing a Dounce homogenizer, a Potter-Elvehjem homegenizer, a French press, etc.) in which cell or tissue suspensions are sheared by forcing them through a narrow space.
  • sonication e.g., utilizing a sonicator
  • Still another example lysis method can include freeze-thaw methods (e.g., utilizing a free or dry ice with ethanol) in which repeated cycles of freezing and thawing disrupt cells through ice crystal formation.
  • another example lysis method can include manual grinding methods (e.g., utilizing mortar and pestle) that involve grinding tissue that is frozen in liquid nitrogen.
  • a lysis method can include detergent-based methods that utilize particular types and concentrations of detergents, buffers, salts and reducing agents to provide results for particular species and types of cells. Enzymatic digestion and osmotic shock are additional examples of lysis methods.
  • a blood-derived serum combined with a lysed white blood cell product can treat various conditions and/or generally stimulate the immune system of an animal.
  • Various dosages or potencies can be implemented and at various different time intervals.
  • Example potencies of a lysed white blood cell product can range from about 0.001% to about 5%, about 0.01% to about 1%, about 0.1% to about 0.5%, or about 0.3%.
  • lysed white blood cell product including an associated carrier substance, medium, or formulation — as applicable
  • potencies of the lysed white blood cell product can be added in many different ratios relative to a blood-derived serum to form a combined lysed white blood cell product-blood derived serum composition.
  • Some example ratios of the lysed white blood cell product relative to a blood-derived serum can include about 1 part lysed white blood cell product to about 1 part blood-derived serum (hereafter expressed in the form “X: Y”), about 1 :2 to about 1 : 10, about 1 :3 to about 1 :8, about 1 :4 to about 1 :6, about 2:1 to about 10: 1, about 3: 1 to about 8:1, or about 4: 1 to about 6: 1.
  • the lysed white blood cell product can be released (e.g., into the bloodstream or local ocular tissue of the animal) within a predetermined time interval, such as within about one second to about five hours, about thirty seconds to about five hours, about fifteen minutes to about five hours, about twenty-five minutes to about four hours, about thirty minutes to about three hours, about sixty minutes to about two hours, or about one hour.
  • an additive can include a combination of the foregoing examples.
  • additional or alternative additives are herein contemplated.
  • an additive can include homeopathic remedies, herbal remedies, corticosteroids, glucocorticoids, nonsteroidal anti-inflammatory drugs, pain reliever drugs, anticholinergics, analgesic, pH balancers, ocular hypertension drugs, glaucoma drugs, carbonic anhydrase inhibitors, beta blockers, antioxidants, immunosuppressive drugs, etc.
  • an additive can include transporter-delivery aids, including nanoparticles, nanomicelles, liposomes, microemulsions and/or enzymes (e.g., to allow delivery of one or more active ingredients notwithstanding various static and dynamic barriers).
  • Static ocular barriers to delivery can include different layers of cornea, sclera, and retina including blood aqueous and blood-retinal barriers.
  • Dynamic ocular barriers to delivery can include choroidal and conjunctival blood flow, lymphatic clearance, and tear dilution.
  • An additive with transporterdelivery aid functionality can also aid ocular delivery despite efflux pumps.
  • additive(s) and the blood-derived serum can be combined in various ways to form a suspension, colloid, solution (e.g., liquid solution), gel, bioadhesive gel, fibrin sealant, or other form-factor for topical ophthalmic delivery (e.g., ocular application on or around the eye).
  • topical ophthalmic delivery can include eye drops placed onto the eye surface, ointment applied on or around the eye, etc.
  • the combination of a blood-derived serum and an additive are implemented with a transmucosal patch such that the active ingredients enter the animal’s blood stream through or across a mucous membrane, such as a tear duct or tear film.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une composition pour une administration ophtalmique topique chez des animaux de compagnie peut comprendre un sérum dérivé du sang et un additif. L'additif peut comprendre au moins un antibiotique, un antihistaminique, une vitamine ou un produit de globules blancs lysés.
PCT/US2025/013143 2024-01-31 2025-01-27 Compositions de sérum avec additif pour administration oculaire chez des animaux Pending WO2025165681A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463627205P 2024-01-31 2024-01-31
US63/627,205 2024-01-31

Publications (1)

Publication Number Publication Date
WO2025165681A1 true WO2025165681A1 (fr) 2025-08-07

Family

ID=96591368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/013143 Pending WO2025165681A1 (fr) 2024-01-31 2025-01-27 Compositions de sérum avec additif pour administration oculaire chez des animaux

Country Status (1)

Country Link
WO (1) WO2025165681A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165710A1 (en) * 2003-02-20 2006-07-27 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
US20200179482A1 (en) * 2018-12-07 2020-06-11 Ohio State Innovation Foundation Composition for and method of facilitating corneal tissue repair
US20220168341A1 (en) * 2016-06-16 2022-06-02 Eye Care International, Llc Compositions and methods of treating dry eye syndrome and other traumatized non-keratinized epithelial surfaces
US20220186191A1 (en) * 2019-01-17 2022-06-16 Boehringer Ingelheim Animal Health USA Inc. Serum-free medium for avian vaccine production and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165710A1 (en) * 2003-02-20 2006-07-27 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
US20220168341A1 (en) * 2016-06-16 2022-06-02 Eye Care International, Llc Compositions and methods of treating dry eye syndrome and other traumatized non-keratinized epithelial surfaces
US20200179482A1 (en) * 2018-12-07 2020-06-11 Ohio State Innovation Foundation Composition for and method of facilitating corneal tissue repair
US20220186191A1 (en) * 2019-01-17 2022-06-16 Boehringer Ingelheim Animal Health USA Inc. Serum-free medium for avian vaccine production and uses thereof

Similar Documents

Publication Publication Date Title
AU2009271129B2 (en) Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
JP5421366B2 (ja) 制御放出性の耳の構造体調節および生来の免疫システム調節化合物および耳の障害の処置のための方法
US9801899B2 (en) Artificial tear emulsion
AU2024204272A1 (en) Compositions and Methods of Use
JP2019517578A (ja) 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
KR20190004815A (ko) 안과 치료제
KR20190057324A (ko) 안검염 치료에 사용되는 약제학적 조성물
KR20100093585A (ko) 덱사메타손 팔미테이트과 같은 코르티코스테로이드 전구약물을 포함하는 안과질환 치료용 조성물
IL263341B1 (en) Stem cell material, compounds and methods of use
EP3362096B1 (fr) Composition de traitement ophtalmique et véhicule pour l'administration de substances pharmaceutiques ou d'agents thérapeutiques
CN104797241B (zh) 水性眼科组合物
RU2432943C1 (ru) Препарат для лечения мастита у коров в период лактации
JP2019123714A (ja) 点眼剤
CA3018636C (fr) Composition ophtalmique stable au stockage
EP4167965B1 (fr) Utilisation d'acide hyaluronique de poids moléculaire élevé en tant que véhicule de transport oculaire
WO2025165681A1 (fr) Compositions de sérum avec additif pour administration oculaire chez des animaux
JP2021533099A (ja) 哺乳動物における自然外側開口部を有する流体含有器官の上皮微生物感染の治療のためのグルココルチコイドの新規使用
US10092510B2 (en) Veterinary method for inducing emesis
WO2023200340A1 (fr) Composés pour réduire la lactation et améliorer la santé
Hakim et al. Medical management of blepharitis
CN100463681C (zh) 一种治疗干眼症的人工泪液
CA2819154A1 (fr) Methodes et compositions pharmaceutiques pour le traitement de troubles du systeme nerveux central avec des agents therapeutiques chez les patients presentant des etats ou des troubles concomitants non lies au systeme nerveux central contre-indiquant l'administration systemique des agents therapeutiques
CN115429749B (zh) 一种复合溶菌酶抑菌凝露及其制备方法
WO2016051179A1 (fr) Composition contenant de la lactoferrine et méthodes de traitement
RU2751876C1 (ru) Средство для профилактики и лечения вагинита у коров

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25748853

Country of ref document: EP

Kind code of ref document: A1